Copyright
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Sep 27, 2023; 15(9): 1013-1020
Published online Sep 27, 2023. doi: 10.4254/wjh.v15.i9.1013
Published online Sep 27, 2023. doi: 10.4254/wjh.v15.i9.1013
Noninvasive prognostic models, imaging, and elastography to predict clinical events in primary sclerosing cholangitis: A review
Mark W Russo, Division of Hepatology, Atrium Health Wake Forest, Charlotte, NC 28204, United States
Author contributions: Russo MW collected and reviewed the articles and wrote the paper.
Conflict-of-interest statement: All the author has no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Mark W Russo, FAASLD, AGAF, FACG, MD, Professor, Divison of Hepatology, Atrium Health Wake Forest, 6th Floor MMP, 1025 Morehead Medical Dr, Charlotte, NC 28204, United States. mark.russo@atriumhealth.org
Received: April 7, 2023
Peer-review started: April 7, 2023
First decision: June 25, 2023
Revised: July 17, 2023
Accepted: August 23, 2023
Article in press: August 23, 2023
Published online: September 27, 2023
Peer-review started: April 7, 2023
First decision: June 25, 2023
Revised: July 17, 2023
Accepted: August 23, 2023
Article in press: August 23, 2023
Published online: September 27, 2023
Core Tip
Core Tip: Several noninvasive prognostic models have been validated that improve upon serum alkaline phosphatase and the Mayo risk score or include subgroups of patients not validated by these tests. The UK-PSC score has superior test performance compared to the Mayo risk score for short and long term transplant free survival. The Primary sclerosing risk estimate tool (PREsTo) has excellent test performance for risk of hepatic decompensation. The Amsterdam-Oxford model includes patients with small duct primary sclerosing cholangitis (PSC) and PSC-autoimmune hepatitis overlap. Elastography and magnetic resonance imaging show promise as prognostic tools.